Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 6/20 | 0.45 |
| ▸ | CDK4 | P11802 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476709 | 0.96 | PRKCD (0.49) | NPC1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL4499929 | 0.81 | JAK2 (0.53) | LMNAHTTPRKCDABL1EGFR | |
| SCHEMBL4476449 | 0.78 | ABL1 (0.45) | PRKCDABL1EGFRPRKCACDK2 | |
| SCHEMBL4484583 | 0.73 | CDK2 (0.68) | CDK2CDK4IKBKBCDK1 | |
| SCHEMBL4480390 | 0.72 | SMG1 (0.45) | PRKCDABL1EGFRPRKCACDK2 | |
| SCHEMBL4783720 | 0.72 | HPGD (0.91) | NPC1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5105343 | 0.71 | CDK2 (0.69) | PRKCDABL1EGFRPRKCACDK2 | |
| SCHEMBL4030132 | 0.71 | CDK2 (0.68) | PRKCDABL1EGFRPRKCACDK2 | |
| SCHEMBL4193367 | 0.71 | CDK2 (0.71) | PRKCDABL1EGFRPRKCACDK2 | |
| SCHEMBL4783422 | 0.70 | HPGD (0.94) | NPC1MAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579344-B2 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | ASTRAZENECA AB (SE) | 2009-08-25 | — | — | US | disclosed |
| US-20060229329-A1 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229329-A1 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | TYMP, CCNI, MKI67 | NPC1 3755/4885MAPT 4035/4885KDM4E 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.